Product news from the 05/16/06 News Brief

Share this article:
Medicis won FDA approval for Solodyn (minocycline HCl, USP) extended release tablets. Solodyn is the only oral minocycline approved for once-daily dosage in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older and the only approved minocycline in extended-release tablet form. Questcor Pharmaceuticals has acquired US rights to Doral (quazepam), a non-narcotic, selective benzodiazepine receptor agonist indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings. Questcor acquires the product from MedPointe for $2.5 million in cash and a future milestone payment of $1.5 million. Gross ex-factory sales for Doral in 2005 were $1.1 million.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.